Company intelligence / Profile preview

Ennovate Pharma

Ownership: Private
Development stage: Preclinical

Overview

Ennovate Pharma develops precision therapeutics for autoimmune and inflammatory diseases, focusing on patients who do not respond to current cytokine-based treatments. The company leverages advanced single-cell spatial biology data combined with standard clinical data, analyzed through proprietary AI/ML algorithms, to rapidly identify new drug targets. Its pipeline includes three preclinical antibody programs targeting key immune pathways relevant to refractory disease populations.

Therapeutic areas: Immunology
Modalities: Monovalent biologics (antibodies)Bifunctional/bispecific biologics (antibodies)
Industry: Biotech

Drug pipeline

6 assets

ENNO-001

Preclinical

5 more assets in the full pipeline.

Partnerships

Co-founded with Enable Medicine and General Inception.Strategic partnership leveraging Enable Medicine’s biological atlas/data platform.

Beyond the preview

Go deeper on Ennovate Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ennovate Pharma.